Real-world outcome of rTMS treatment for depression within the Japanese public health insurance system: Registry data from Kansai TMS network.

This study registered consecutive cases to elucidate the efficacy of rTMS treatment for depression within the Japanese public health insurance system. Of the 102 patients with depression who received rTMS over the left dorsolateral prefrontal cortex, 44 (43.1 %) patients reached remission and 14 (13.7 %) patients did not reach remission but responded to treatment. No serious adverse events occurred. Low baseline HAMD-17 score was associated with remission after rTMS treatment. Favorable outcomes of rTMS treatment were shown in this cohort within the Japanese public insurance system. Our results provide insights into rTMS treatment for depression in real-world clinical setting.
Competing Interests: Declaration of Competing Interest Authors Imazu, Ikeda, Shinosaki, and Takahashi have received speaker honoraria from Teijin Pharma Limited. Author Kanazawa has received materials supervision fee from Teijin Pharma Limited.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)